Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Earth Science TechETST -10.83%36 EV-to-EBITDA is 8.49 as of Jul. 27, 2026. GuruFocus rates ETST with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 742 Drug Manufacturers companies, Earth Science Tech ranks better than 63.48% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Earth Science Tech's enterprise value is $28.81 Mil.
Earth Science Tech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $3.39 Mil. Therefore, Earth Science Tech's EV-to-EBITDA for today is 8.49.
The historical rank and industry rank for Earth Science Tech's EV-to-EBITDA or its related term are showing as below:
ETST'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -213.48 Med: -0.42 Max: 74.36
Current: 8.49
During the past 13 years, the highest EV-to-EBITDA of Earth Science Tech was 74.36. The lowest was -213.48. And the median was -0.42.
ETST's EV-to-EBITDA is ranked better than 63.48% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.93
vs ETST: 8.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Earth Science Tech's PE Ratio (TTM) for today is calculated as:
Earth Science Tech's share price for today is $0.107.
Earth Science Tech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Earth Science Tech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Earth Science Tech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Earth Science Tech EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Earth Science Tech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Earth Science Tech's EV-to-EBITDA falls into.
Earth Science Tech's current Enterprise Value is $28.81 Mil.
Earth Science Tech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Earth Science Tech (ETST) has a EV-to-EBITDA of 8.49 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Earth Science Tech. According to the industry distribution chart, Earth Science Tech ranks #271 out of 742 companies in the Drug Manufacturers industry, placing it in the top 36.5%.
Is Earth Science Tech's EV-to-EBITDA too high?
Earth Science Tech's current EV-to-EBITDA is 8.49. The Drug Manufacturers industry median EV-to-EBITDA is 12.93. Earth Science Tech's value of 8.49 is 34.3% below this industry median. Based on the distribution chart, Earth Science Tech ranks #271 out of 742 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Earth Science Tech has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Earth Science Tech's EV-to-EBITDA compare to IXHL and SCYX?
According to the Drug Manufacturers industry distribution chart, Earth Science Tech ranks #271 out of 742 companies for EV-to-EBITDA. This puts Earth Science Tech in the upper half of its industry. The industry median EV-to-EBITDA is 12.93. Earth Science Tech's value of 8.49 is 34.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.93, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Earth Science Tech's current EV-to-EBITDA of 8.49 is 34.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Earth Science Tech. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Earth Science Tech's current EV-to-EBITDA is 8.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Earth Science Tech stock overvalued right now?
Earth Science Tech (ETST) has a current EV-to-EBITDA of 8.49. The current EV-to-EBITDA is 8.49 and 34.3% below the Drug Manufacturers industry median of 12.93. Earth Science Tech's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Earth Science Tech (ETST), the current EV-to-EBITDA is 8.49 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Earth Science Tech Inc is a diversified holding company. The company focuses on the health and wellness sector. The Company's principal operating plan is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company's healthcare operations are supported by investments in real estate and asset management activities and a consumer products business. The core of the Company's value proposition is the seamless integration of patient care, from consultation to fulfillment.
36GF Score
Get the complete analysis for ETST
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ETST has been successfully added to your 
